Advances in lipid nanodispersions for parenteral drug delivery and targeting

Rossi, 2007, Principles in the development of intravenous lipid emulsions, 88 Torchilin, 2007, Lipid-based parenteral drug delivery systems: biological implications, 48 Constantinides, 2004, Tocol emulsions for drug solubilization and parenteral delivery, Adv. Drug Del. Rev., 56, 1243, 10.1016/j.addr.2003.12.005 Constantinides, 2006, Advances in the use of tocols as drug delivery vehicles, Pharm. Res., 23, 243, 10.1007/s11095-005-9262-9 Sarker, 2005, Engineering of nanoemulsions for drug delivery, Cur. Drug Deliv., 2, 297, 10.2174/156720105774370267 Muller, 1998, Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size reduction technique, Int. J. Pharm., 160, 229, 10.1016/S0378-5173(97)00311-6 Rabinow, 2004, Nanosuspensions in drug delivery, Nature Rev., 3, 785, 10.1038/nrd1494 Sutton, 2007, Functionalized micellar systems for cancer targeted drug delivery, Pharm. Res., 24, 1029, 10.1007/s11095-006-9223-y Torchilin, 2007, Micellar nanocarriers: pharmaceutical perspectives, Pharm. Res., 24, 1, 10.1007/s11095-006-9132-0 Kwon, 2003, Polymeric micelles for delivery of poorly water-soluble compounds, Crit. Rev. Ther. Drug Carr. Syst., 20, 357, 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20 Sparreboom, 1999, Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications, Cancer Res., 59, 1454 van Zuylen, 2001, Role of formulation vehicles in taxane pharmacology, Invest. New Drugs, 19, 125, 10.1023/A:1010618632738 Dye, 1980, Suspected anaphylactic reaction to Cremophor EL, Br. Med. J., 280, 1353, 10.1136/bmj.280.6228.1353 Gelderblom, 2001, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, Eur. J. Cancer, 37, 1590, 10.1016/S0959-8049(01)00171-X Tadros, 2004, Formation and stability of nanoemulsions, Adv. Colloid Interface Sci., 109, 303, 10.1016/j.cis.2003.10.023 Shafiq-un-Nabi, 2007, Formulation development and optimization using nanoemulsion technique: a technical note, AAPS Pharm. Sci. Tech., 8, 28, 10.1208/pt0802028 Constantinides, 1995, Particle size of phase inverted water-in-oil microemulsions under different dilution and storage conditions, Int. J. Pharm., 115, 225, 10.1016/0378-5173(94)00272-7 Unger, 2004, Therapeutic applications of lipid-coated microbubbles, Adv. Drug Del. Rev., 56, 1291, 10.1016/j.addr.2003.12.006 Anton, 2007, Salting-out effect induced by temperature cycling of a water/nonionic surfactant/oil system, J. Phys. Chem. B, 111, 3651, 10.1021/jp0664768 Qiu, 2006, Polymer architecture and drug delivery, Pharm. Res., 23, 1, 10.1007/s11095-005-9046-2 Wissing, 2004, Solid lipid nanoparticles for parenteral delivery, Adv. Drug Del. Rev., 56, 1257, 10.1016/j.addr.2003.12.002 Lukyanov, 2004, Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs, Adv. Drug Del. Rev., 56, 1273, 10.1016/j.addr.2003.12.004 Foster, 1995, Influence of microemulsion phases on the preparation of fine-disperse emulsions, Adv. Colloid Interface Sci., 58, 119, 10.1016/0001-8686(95)00247-N Rons, 2003, Formation and properties of miniemulsions formed by microemulsions dilution, Adv. Colloid Interface Sci., 106, 129, 10.1016/S0001-8686(03)00108-8 Washington, 1988, The production of parenteral feeding emulsions by microfluidizer, Int. J. Pharm., 44, 169, 10.1016/0378-5173(88)90113-5 Pinnamaneni, 2003, Comparison of oil-in-water emulsions manufactured by microfluidization and homogenization, Pharmazie, 58, 554 Jorgensen, 2006, Preparing and evaluating delivery systems for proteins, Eur. J. Pharm. Sci., 29, 174, 10.1016/j.ejps.2006.05.008 Moschwitzer, 2006, New method for the effective production of ultrafine drug nanocrystals, J. Nanosci. Nanotechnol., 6, 3145, 10.1166/jnn.2006.480 Mouton, 2006, Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation, Antimicrob. Agents Chemother., 50, 4096, 10.1128/AAC.00630-06 Dou, 2006, Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery, Blood, 108, 2827, 10.1182/blood-2006-03-012534 Van Eerdenbrugh, 2007, Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling, Int. J. Pharm., 338, 198, 10.1016/j.ijpharm.2007.02.005 Rowinsky, 1995, Paclitaxel (Taxol®), New Engl. J. Med., 332, 1004, 10.1056/NEJM199504133321507 Singla, 2002, Paclitaxel and its formulations, Int. J. Pharm., 235, 179, 10.1016/S0378-5173(01)00986-3 Collins-Gold, 1990, Parenteral emulsions for drug delivery, Adv. Drug Del. Rev., 5, 189, 10.1016/0169-409X(90)90016-L Tarr, 1987, A new parenteral emulsion for the administration of Taxol®, Pharm. Res., 4, 162, 10.1023/A:1016483406511 Lundberg, 1997, A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol®l), J. Pharm. Pharmacol., 49, 16, 10.1111/j.2042-7158.1997.tb06744.x Simamora, 1998, Emulsion formulations for intravenous administration of paclitaxel, J. Pharm. Sci. Technol., 52, 170 Constantinides, 2000, Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel, Pharm. Res., 17, 175, 10.1023/A:1007565230130 Spigel, 2002 Gorelov, 2004 Lissianskaya, 2004 Bogdanova, 2005 Dreher, 2006, Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers, J. Natl. Cancer Inst., 98, 335, 10.1093/jnci/djj070 Iyer, 2006, Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discov. Today, 11, 812, 10.1016/j.drudis.2006.07.005 D'Arrigo, 1991, Lipid-coated uniform microbubbles for earlier sonographic detection of brain tumors, J. Neuroimaging, 1, 134, 10.1111/jon199113134 Simon, 1992, A quantitative assessment of tumor enhancement by ultrastable lipid-coated microbubbles as a contrast agent, Invest. Radiol., 27, 29, 10.1097/00004424-199201000-00003 D'Arrigo, 1993, Detection of experimental rat liver tumors by contrast-assisted ultrasonography, Invest. Radiol., 28, 218, 10.1097/00004424-199303000-00006 Simon, 1993, Applications of lipid-coated microbubble ultrasonic contrast to tumor therapy, Ultrasound Med. & Biol., 19, 123, 10.1016/0301-5629(93)90004-8 Simon, 1990, Lipid-coated ultrastable microbubbles as a contrast agent in neurosonography, Invest. Radiol., 25, 1300, 10.1097/00004424-199012000-00005 D'Arrigo, 1991, Contrast-assisted tumor detection, Drug News & Perspect., 4, 164 Barbarese, 1995, Internalization of microbubbles by tumor cells in vivo and in vitro, J. Neuro-Oncology, 26, 25, 10.1007/BF01054766 Ho, 1997, Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in brain tumor therapy, Neurosurgery, 40, 1260, 10.1097/00006123-199706000-00028 D'Arrigo, 1978, Improved method for studying the surface chemistry of bubble formation, Aviat. Space Environ. Med., 49, 358 D'Arrigo, 1979, Bubble production in agarose gels subjected to different decompression schedules, Undersea Biomed. Res., 6, 93 D'Arrigo, 1979, Physical properties of the nonionic surfactants surrounding gas cavitation nuclei, J. Chem. Phys., 71, 1809, 10.1063/1.438531 D'Arrigo, 1980, Structural features of the nonionic surfactants stabilizing long-lived bubble nuclei, J. Chem.Phys., 72, 5133, 10.1063/1.439746 D'Arrigo, 1981, Aromatic proteinaceous surfactants stabilize long-lived gas microbubbles from natural sources, J. Chem.Phys., 75, 962, 10.1063/1.442096 D'Arrigo, 1983, Glycoprotein surfactants stabilize long-lived gas microbubbles in the environment, 124 D'Arrigo, 1983, Biological surfactants stabilizing natural microbubbles in aqueous media, Adv. Colloid. Interface Sci., 19, 253, 10.1016/0001-8686(83)85001-5 D'Arrigo, 1984, Geochemical properties and biochemical composition of the surfactant mixture surrounding natural microbubbles, J. Colloid & Interface Sci., 100, 96, 10.1016/0021-9797(84)90414-4 D'Arrigo, 1984, Surface properties of microbubble-surfactant monolayers at the air/water interface, J. Colloid & Interface Sci., 100, 106, 10.1016/0021-9797(84)90415-6 D'Arrigo, 1986 J.S. D'Arrigo. Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures. U.S. Patent No. 4,684,479 (1987). D'Arrigo, 1992, Physical characteristics of ultrastable lipid-coated microbubbles, J. Colloid & Interface Sci., 149, 592, 10.1016/0021-9797(92)90447-T D'Arrigo, 1998, Uptake of lipid-coated microbubbles by tumors: drug delivery by receptor-mediated endocytosis Vitols, 1984, Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation, Blood, 63, 1186, 10.1182/blood.V63.5.1186.1186 Gal, 1981, Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms, Am. J. Obstet. Gynecol., 139, 877, 10.1016/0002-9378(81)90952-2 Vitols, 1985, Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts, J. Med. Chem., 28, 451, 10.1021/jm00382a011 Vitols, 1992, Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo, Cancer Res., 52, 6244 Rudling, 1983, Delivery of aclacinomycin A to human glioma cells in vitro by the low density lipoprotein pathway, Cancer Res., 43, 4600 Huang, 1992, Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice, Cancer Res., 52, 5135 Moghimi, 2003, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Progress. Lipid Res., 42, 463, 10.1016/S0163-7827(03)00033-X Krieger, 1994, Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors, and LDL receptor-related protein (LRP), Ann. Rev. Biochem., 63, 601, 10.1146/annurev.bi.63.070194.003125 Clement, 1992, Tissue distribution and plasma clearance of a novel microcrystalline-coated flurbiprofen formulation, Pharmacologist, 34, 204 Shenoy, 2005, Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies, Pharm. Res., 22, 2107, 10.1007/s11095-005-8343-0 Rabinow, 2007, Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat, Int. J. Pharm., 339, 251, 10.1016/j.ijpharm.2007.02.030 Merisko-Liversidge, 1996, Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, Pharm. Res., 13, 272, 10.1023/A:1016051316815 Peters, 2000, Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection, J. Antimicrob. Chemother., 45, 77, 10.1093/jac/45.1.77 Scholer, 2001, Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis, Antimicrob. Agents Chemother., 45, 1771, 10.1128/AAC.45.6.1771-1779.2001 E. Olavarria, M. Hassan, A. Eades, C. Nilsson, A. Timms, J. Matthews, C. Craddock, E. Kanfer, J. Apperley, J. Goldman. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia. 14 (200) 1954–1959. Gradishar, 2005, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J. Clin. Oncol., 23, 7794, 10.1200/JCO.2005.04.937 Ibrahim, 2002, Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel, Clin. Cancer Res., 8, 1038 Ibrahim, 2005, Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer, J. Clin. Oncol., 23, 6019, 10.1200/JCO.2005.11.013